Continuous ambulatory peritoneal dialysis and the human immunodeficiency virus

Area of Science:

• Nephrology
• Infectious Diseases
• Immunology

Background:

• End-stage renal disease (ESRD) presents unique challenges in human immunodeficiency virus (HIV)-infected individuals.
• Continuous ambulatory peritoneal dialysis (CAPD) is a treatment option for ESRD, but its application in HIV-positive patients requires careful consideration.
• The peritoneal dialysis effluent (PDE) from HIV-infected patients may pose an infectious risk.

Purpose of the Study:

• To review the clinical performance of CAPD in HIV-infected individuals with ESRD.
• To evaluate the infectious potential of PDE in this patient population.
• To suggest methods for managing and minimizing infectious risks associated with CAPD in HIV-positive ESRD patients.

Main Methods:

• Literature review of studies on CAPD in HIV-infected ESRD patients.
• Analysis of data on clinical outcomes and complications.
• Assessment of the infectious properties of peritoneal dialysis effluent.

Main Results:

• Clinical performance data for CAPD in HIV-infected ESRD patients were analyzed.
• The potential for peritoneal dialysis effluent to transmit infection was evaluated.
• Strategies to mitigate infectious risks were identified.

Conclusions:

• CAPD can be a viable treatment option for selected HIV-infected ESRD patients.
• Careful patient selection and monitoring are crucial.
• Implementing specific protocols can reduce the infectious risk associated with PDE.